BCRX

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change +0.35
Percentage change 3.92	%

Peers: VRTX REGN IONS ALNY SRPT PTCT BMRN CRSP BLUE RARE

| Held by: VTI IWM VXF XBI VB IWO VBK VTWO IBB SCHA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.26	Insider Own	4.24%	Shs Outstand	209.21M	Perf Week	1.50%
Market Cap	1.91B	Forward P/E	18.78	EPS next Y	0.49	Insider Trans	0.00%	Shs Float	200.37M	Perf Month	-17.26%
Enterprise Value	2.45B	PEG	-	EPS next Q	0.00	Inst Own	84.36%	Short Float	11.52%	Perf Quarter	34.54%
Income	-53.47M	P/S	3.80	EPS this Y	125.16%	Inst Trans	5.66%	Short Ratio	4.90	Perf Half Y	18.64%
Sales	503.49M	P/B	-	EPS next Y	349.58%	ROA	-11.28%	Short Interest	23.08M	Perf YTD	21.48%
Book/sh	-2.16	P/C	6.47	EPS next 5Y	-	ROE	-	52W High	11.31 -19.23%	Perf Year	40.11%
Cash/sh	1.41	P/FCF	-	EPS past 3/5Y	25.20% 14.52%	ROIC	-15.72%	52W Low	6.01 51.87%	Perf 3Y	-15.73%
Dividend Est.	-	EV/EBITDA	71.00	Sales past 3/5Y	42.07% 55.97%	Gross Margin	96.64%	Volatility	2.45% 3.35%	Perf 5Y	86.05%
Dividend TTM	-	EV/Sales	4.86	EPS Y/Y TTM	75.79%	Oper. Margin	6.59%	ATR (14)	0.36	Perf 10Y	-38.81%
Dividend Ex-Date	-	Quick Ratio	2.88	Sales Y/Y TTM	41.67%	Profit Margin	-10.62%	RSI (14)	38.87	Recom	1.18
Dividend Gr. 3/5Y	- -	Current Ratio	2.93	EPS Q/Q	100.06%	SMA20	-5.78%	Beta	1.11	Target Price	16.64
Payout	-	Debt/Eq	-	Sales Q/Q	56.89%	SMA50	-8.64%	Rel Volume	0.68	Prev Close	8.79
Employees	580	LT Debt/Eq	-	Earnings	May 05 BMO	SMA200	9.87%	Avg Volume	4.71M	Price	9.14
IPO	Mar 04, 1994	Option/Short	Yes / Yes	EPS/Sales Surpr.	100.00% 13.89%	Trades		Volume	1,320,594	Change	3.92%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight	$20
Feb-25-25	Initiated	Wedbush	Outperform	$15
Nov-20-23	Resumed	JP Morgan	Overweight	$10
Sep-18-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$9 → $10
Aug-04-23	Upgrade	Jefferies	Hold → Buy	$11
Jul-13-23	Upgrade	BofA Securities	Neutral → Buy	$10
Feb-22-23	Upgrade	Needham	Hold → Buy	$14
Nov-02-22	Upgrade	Evercore ISI	In-line → Outperform	$14 → $16
Aug-05-22	Downgrade	Oppenheimer	Outperform → Perform
Aug-05-22	Downgrade	Evercore ISI	Outperform → In-line	$14
Apr-18-22	Downgrade	Barclays	Overweight → Equal Weight	$22 → $13
Apr-11-22	Downgrade	BofA Securities	Buy → Neutral	$21 → $14
Dec-10-21	Initiated	Oppenheimer	Outperform	$16
Aug-06-21	Downgrade	Jefferies	Buy → Hold
Aug-03-21	Initiated	Cantor Fitzgerald	Overweight	$21
Mar-01-21	Initiated	Cowen	Outperform	$16
Sep-29-20	Resumed	JP Morgan	Overweight	$7
Jun-17-20	Initiated	BTIG Research	Neutral
May-05-20	Upgrade	Barclays	Equal Weight → Overweight	$7
Nov-15-19	Upgrade	BofA/Merrill	Neutral → Buy	$5 → $4

Show Previous Ratings

Today 07:00AM	BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit (GlobeNewswire)
Jul-07-25 09:40AM	Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year? (Zacks)
07:00AM	BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development (GlobeNewswire)
Jul-06-25 04:00AM	BioCryst Pharmaceuticals Sells European ORLADEYO Business for Up to $264M (Insider Monkey)
Jul-03-25 01:51PM	Ensign Group Boosts U.S. Presence With Idaho and Texas Facility Buyouts (Zacks)
07:00AM	Loading…
07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-30-25 01:05PM	Select Medical Expands Presence in Tennessee With Ballad Health Deal (Zacks)
Jun-27-25 07:00AM	BioCryst Announces Sale of European ORLADEYO (berotralstat) Business to Neopharmed Gentili for up to $264 Million (GlobeNewswire)
Jun-26-25 04:32AM	Zacks.com featured highlights ASR, INSW, BCRX, ASC and RRGB (Zacks)
Jun-25-25 12:00PM	BioCryst (BCRX) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
07:51AM	5 Must-Buy Efficient Stocks to Buy for Solid Gains Amid Volatility (Zacks)
06:16AM	New Strong Buy Stocks for June 25th (Zacks)
Jun-18-25 09:40AM	Is GEN DIGITAL INC (GEN) Stock Outpacing Its Business Services Peers This Year? (Zacks)
09:40AM	Is Atmos Energy (ATO) Outperforming Other Utilities Stocks This Year? (Zacks)
09:40AM	Is Apollo Commercial Real Estate Finance (ARI) Stock Outpacing Its Finance Peers This Year? (Zacks)
09:40AM	Loading…
09:40AM	Has Heico (HEI) Outpaced Other Aerospace Stocks This Year? (Zacks)
09:40AM	Has ASML Holding (ASML) Outpaced Other Computer and Technology Stocks This Year? (Zacks)
09:40AM	Has Aris Mining Corporation (ARMN) Outpaced Other Basic Materials Stocks This Year? (Zacks)
09:40AM	Are Medical Stocks Lagging Acurx Pharmaceuticals (ACXP) This Year? (Zacks)
09:40AM	Are Industrial Products Stocks Lagging Andritz (ADRZY) This Year? (Zacks)
09:40AM	Are Construction Stocks Lagging AECOM (ACM) This Year? (Zacks)
Jun-16-25 07:00AM	BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO (berotralstat) Across all Ages at EAACI (GlobeNewswire)
Jun-13-25 07:00AM	ORLADEYO (berotralstat) Approved in Colombia (GlobeNewswire)
02:32AM	United Therapeutics (UTHR) Soars 3.5%: Is Further Upside Left in the Stock? (Zacks)
Jun-06-25 07:00AM	BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries (GlobeNewswire)
Jun-04-25 12:00PM	BioCryst Pharmaceuticals (BCRX) is a Great Momentum Stock: Should You Buy? (Zacks)
10:00AM	Best Momentum Stock to Buy for June 4th (Zacks)
05:52AM	New Strong Buy Stocks for June 4th (Zacks)
Jun-03-25 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-02-25 07:00AM	BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology (GlobeNewswire)
07:00AM	Loading…
May-30-25 07:00AM	BioCryst Highlights Real-world Data Showing ORLADEYO (berotralstat) Consistently Reduces HAE Attacks Across All Ages (GlobeNewswire)
May-28-25 09:40AM	Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year? (Zacks)
May-27-25 07:00AM	BioCryst to Present at Upcoming Investor Conferences (GlobeNewswire)
May-26-25 09:55AM	Wall Street Analysts Believe BioCryst (BCRX) Could Rally 55.81%: Here's is How to Trade (Zacks)
May-16-25 07:00AM	BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO (berotralstat) (GlobeNewswire)
May-15-25 09:40AM	FDA awards BioCrysts Orladeyo NDA for paediatric HAE (Pharmaceutical Technology)
May-14-25 07:00AM	BioCryst Announces FDA Acceptance of NDA for ORLADEYO (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years (GlobeNewswire)
May-09-25 10:00AM	Best Momentum Stocks to Buy for May 9th (Zacks)
07:08AM	New Strong Buy Stocks for May 9th (Zacks)
May-08-25 12:20PM	Why BioCryst (BCRX) Might be Well Poised for a Surge (Zacks)
12:00PM	What Makes BioCryst Pharmaceuticals (BCRX) a Strong Momentum Stock: Buy Now? (Zacks)
09:55AM	Does BioCryst (BCRX) Have the Potential to Rally 61.21% as Wall Street Analysts Expect? (Zacks)
May-06-25 04:50AM	Why BioCryst Pharmaceuticals, Inc. (BCRX) Soared on Monday (Insider Monkey) -6.89%
03:02AM	BioCryst Pharmaceuticals Inc (BCRX) Q1 2025 Earnings Call Highlights: Strong ORLADEYO Sales ... (GuruFocus.com)
12:56AM	Q1 2025 BioCryst Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
May-05-25 02:05PM	BioCryst: Strong Opportunity For A Double With A Proven Therapy (Seeking Alpha) +23.52%
12:54PM	BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2025 Earnings Call Transcript (Seeking Alpha)
08:20AM	BioCryst Pharmaceuticals (BCRX) Reports Break-Even Earnings for Q1 (Zacks)
07:00AM	BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-02-25 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-01-25 07:00AM	BioCryst Appoints Steve Frank to Board of Directors (GlobeNewswire)
Apr-30-25 10:01AM	Inotiv, Inc. (NOTV) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
07:00AM	BioCryst to Present at Upcoming Investor Conferences (GlobeNewswire)
Apr-28-25 10:00AM	BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Apr-21-25 07:00AM	BioCryst to Report First Quarter 2025 Financial Results on May 5 (GlobeNewswire)
Apr-10-25 05:21PM	How BioCryst Pharmaceuticals, Inc. (BCRX) Stock Stands Out in a Strong Industry (Zacks) -5.32% +6.40%
Apr-04-25 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.82%
Apr-02-25 04:01PM	BioCryst to Present at Upcoming Investor Conference (GlobeNewswire)
Mar-06-25 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-01-25 09:13AM	Is BioCryst Pharmaceuticals, Inc. (BCRX) the Best Small-Cap Stock to Buy Now? (Insider Monkey)
Feb-27-25 10:30AM	BioCryst (BCRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
Feb-26-25 09:55AM	Here's Why BioCryst (BCRX) Could be Great Choice for a Bottom Fisher (Zacks)
09:55AM	Wall Street Analysts Predict an 84.18% Upside in BioCryst (BCRX): Here's What You Should Know (Zacks)
Feb-25-25 02:28AM	Q4 2024 BioCryst Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
02:01AM	BioCryst Pharmaceuticals Inc (BCRX) Q4 2024 Earnings Call Highlights: Strong ORLADEYO Revenue ... (GuruFocus.com)
Feb-24-25 06:15PM	Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today (Motley Fool) -9.99%
04:30PM	BioCryst Pharmaceuticals (BCRX) Q4 2024 Earnings Call Transcript (Motley Fool)
08:10AM	BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:17AM	BioCryst: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones (GlobeNewswire)
06:00AM	BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to (GlobeNewswire)
Feb-19-25 07:00AM	BioCryst to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-17-25 10:00AM	BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Feb-12-25 07:00AM	BioCryst Launches ORLADEYO (berotralstat) in Portugal (GlobeNewswire)
Feb-10-25 08:30AM	BioCryst to Present New ORLADEYO (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress (GlobeNewswire)
07:00AM	BioCryst to Report Fourth Quarter 2024 Financial Results on February 24 (GlobeNewswire)
Feb-04-25 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.17%
Jan-14-25 08:35AM	BioCryst price target raised to $12 from $10 at Evercore ISI (TipRanks) -8.83%
Jan-10-25 07:00AM	BioCryst Announces Preliminary Full Year 2024 ORLADEYO (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y) (GlobeNewswire)
Jan-07-25 07:00AM	BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-06-25 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-04-24 04:15PM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.96%
Nov-18-24 02:00AM	BioCryst Launches ORLADEYO (berotralstat) in Ireland (GlobeNewswire)
Nov-06-24 07:00AM	BioCryst to Present at Upcoming Investor Conferences (GlobeNewswire) +9.57%
Nov-05-24 07:29AM	BioCryst Announces Strong Q3 2024 Revenue Growth (TipRanks)
07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
02:32AM	Q3 2024 BioCryst Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
02:03AM	BioCryst Pharmaceuticals Inc (BCRX) Q3 2024 Earnings Call Highlights: Strong ORLADEYO Growth ... (GuruFocus.com)
Nov-04-24 02:30PM	BioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings Call Transcript (Motley Fool) -12.81%
08:10AM	BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:06AM	BioCryst: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-24-24 08:00AM	BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO (berotralstat) (GlobeNewswire)
Oct-23-24 09:55AM	How Much Upside is Left in BioCryst (BCRX)? Wall Street Analysts Think 79.5% (Zacks)
Oct-21-24 07:00AM	BioCryst to Report Third Quarter 2024 Financial Results on November 4 (GlobeNewswire)
Oct-17-24 03:05PM	State Street Corp's Strategic Reduction in BioCryst Pharmaceuticals Holdings (GuruFocus.com)
Oct-14-24 07:00AM	BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO (berotralstat) (GlobeNewswire)
Oct-11-24 12:15PM	Is BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) The Top Stock With Improving Technical Ratings According To Piper Sandler? (Insider Monkey)
Oct-10-24 07:00AM	BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting (GlobeNewswire)
Oct-09-24 08:03AM	BioCryst Pharmaceuticals, Inc. (BCRX) Surpasses Revenue Expectations by $11 Million in Q2 (Insider Monkey)

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hutson Nancy J	Director	Dec 13 '24	Sale	7.54	7,000	52,780	86,638	Dec 16 04:35 PM
Hutson Nancy J	Director	Dec 13 '24	Proposed Sale	7.51	7,000	52,584		Dec 13 04:23 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Biocryst Pharmaceuticals Inc

Upgrade your FINVIZ experience